.jpg "Leah B. Sansbury, PhD, MSPH photo")
Senior Director, Global Epidemiology
Ultragenyx Pharmaceutical
Chapel Hill, North Carolina, United States
Dr. Sansbury is Director of Epidemiology and a member of the Oncology Epidemiology Therapeutic Team in the Value Evidence and Outcomes Department at GlaxoSmithKline (GSK). Dr. Sansbury first joined GSK in 2011, providing epidemiologic support to the oncology pipeline. Since 2011, Dr. Sansbury has served as the lead Epidemiologist for several assets in both oncology and respiratory medicine. She has conducted epidemiologic research across the drug and development lifecycle, with a focus on real-world evidence generation and drug safety for hematologic and solid tumor immunotherapy and use of inhaled triple maintenance therapy among COPD and asthma patients. Dr. Sansbury’s pharmacoepidemiology experience also includes conducting post-authorisation safety studies (PASS) and risk evaluation and mitigation strategies (REMS), as well as providing data for other key regulatory documents for the FDA and EMA. Prior to joining GSK in 2011, Dr. Sansbury was an Epidemiologist in the Epidemiology and Genetics Research Program at the National Cancer Institute (NCI). At the NCI, Dr. Sansbury was responsible for a large research portfolio and initiatives that focus on etiologic and genetic factors that influence cancer progression, recurrence and survival, including research in the area of pharmacoepidemiology and pharmacogenomics. Dr. Sansbury received her M.S.P.H and her Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill.
Disclosure information not submitted.
Saturday, August 27, 2022
1:00 PM – 2:30 PM CEST